EpicentRx is an innovation-driven clinical-stage drug and device company with focus on minimally toxic therapies for cancer and chronic disease indications with an emphasis on quality of life during treatment. EpicentRx’s lead CyNRGY platform candidate, RRx-001, has been tested in several clinical trials including an ongoing Phase 3 study in small cell lung cancer. It is among a portfolio of small molecule compounds that favorably alter the tumor microenvironment, antagonizing CD47 and activating tumor associated macrophages (TAMs) as well as down regulating inflammation through inhibition of inflammasomes and activation of Nrf2. The company is also advancing multiple products through its AdAPT platform, built around a next generation viral vector (TAV-255), and highlighted by the clinical stage AdAPT-001, designed to selectively infect tumors to bring an immune response against cancer. In addition TAV-255 is being used for development of personalized cancer vaccines, designed to express cancer specific neoantigens to drive immune activation.